The evidence from clinical trials for malaria vaccine MSP1 42-C1 and COVID-19 vaccine SCB-2019 suggested that the CpG was a safe and potent adjuvant and could be further used in the next generation of vaccines (42, 43). Here, ATAD1 is linked to malaria.